Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/30/2007CA2642243A1 Rapamycin derivatives for treating neuroblastoma
08/30/2007CA2642229A1 Compositions and methods for inhibition of the jak pathway
08/30/2007CA2642216A1 New crystal forms and pharmaceutical compositions of (+)-r-zileuton
08/30/2007CA2642167A1 Fluoroquinolone compositions
08/30/2007CA2642104A1 Fluoroquinolone carboxylic acid salt compositions
08/30/2007CA2642101A1 Benzimidazolone derivatives for the treatment of urinary incontinence
08/30/2007CA2642097A1 Improved preparation of molecular imprinted polymers
08/30/2007CA2642048A1 Phenylephrine containing liquid formulations
08/30/2007CA2641790A1 Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
08/30/2007CA2641670A1 Substituted quinazolines as pde10 inhibitors
08/30/2007CA2640997A1 Doxorubicin formulations for anti-cancer use
08/30/2007CA2640924A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
08/30/2007CA2640723A1 Aliskiren nitrate salt
08/30/2007CA2640331A1 Stabilized pharmaceutical composition
08/30/2007CA2640131A1 Combinations of steroids and methylxanthine compounds
08/30/2007CA2638829A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
08/30/2007CA2638124A1 Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
08/30/2007CA2638095A1 New compounds
08/30/2007CA2637620A1 Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
08/30/2007CA2637573A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives
08/30/2007CA2637531A1 Compounds having 5-ht6 receptor affinity
08/30/2007CA2637214A1 Process for preparing 8-azabicylo[3.2.1]octan-3-one intermediates to 5-ht4 receptor agonist compounds
08/30/2007CA2618741A1 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
08/29/2007EP1826569A1 Identifying material from a breast duct
08/29/2007EP1826216A1 Glp-1 derivatives
08/29/2007EP1826213A1 Rapamycin analogs containing an antioxidant moiety
08/29/2007EP1826212A1 Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
08/29/2007EP1826211A1 Isomers and 42-Epimers of rapamycin alkyl ether analogs, methods of making and using the same
08/29/2007EP1826207A1 Acid salt of benzimidazole derivative and crystal thereof
08/29/2007EP1826205A1 Novel raloxifene succinic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
08/29/2007EP1826203A1 Composition containing flavan compound
08/29/2007EP1826201A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
08/29/2007EP1826198A1 Method for the synthesis of the sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid
08/29/2007EP1826197A1 Aminocarboxylic acid derivative and medicinal use thereof
08/29/2007EP1825866A1 Solid preparation
08/29/2007EP1825861A2 Anti-inflammatory extract and agent and method for the production thereof
08/29/2007EP1825858A1 Composition for promoting osteogenesis and increasing bone mineral content
08/29/2007EP1825857A1 Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer
08/29/2007EP1825856A1 Oral composition containing difructose anhydride
08/29/2007EP1825855A1 Product containing prostaglandin having fluorine atom in molecule
08/29/2007EP1825854A1 MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
08/29/2007EP1825853A2 Methods for treating conditions modulated by lactosyceramide
08/29/2007EP1825852A1 ST104P as an anti-angiogenic agent
08/29/2007EP1825851A2 Combination therapy for effecting weight loss and treating obesity
08/29/2007EP1825850A1 Use of resveratrol and derivatives thereof for promoting the wellness state in mammals
08/29/2007EP1825849A1 Transdermal therapeutic system comprising fentanyl
08/29/2007EP1825848A2 Stable pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
08/29/2007EP1825847A2 Fluvastatin sodium pharmaceutical compositions
08/29/2007EP1825846A2 Implantable device formed from solution processing
08/29/2007EP1824975A2 Lna oligonucleotides and the treatment of cancer
08/29/2007EP1824957A2 Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
08/29/2007EP1824871A1 Macrolone compounds
08/29/2007EP1824870A1 Macrolones - amino substituted quinolones
08/29/2007EP1824869A1 Macrolone compounds
08/29/2007EP1824863A1 Silicon compounds and their use
08/29/2007EP1824862A1 Silicon compounds and their use
08/29/2007EP1824861A2 Lipase inhibitors
08/29/2007EP1824860A2 Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
08/29/2007EP1824859A1 Substituted thieno[2,3-c]pyrazoles, method for the preparation thereof, compositions containing them and use thereof
08/29/2007EP1824856A1 2,4 (4,6) pyrimidine derivatives
08/29/2007EP1824855A1 Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy
08/29/2007EP1824854A2 Substituted pteridines for treating inflammatory diseases
08/29/2007EP1824853A1 Novel spirotropane compounds and methods for the modulation of chemokine receptor activity
08/29/2007EP1824851A2 Novel diazabicyclononene derivative
08/29/2007EP1824850A2 SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
08/29/2007EP1824849A2 Inhibitors of akt activity
08/29/2007EP1824848A1 Fused bicycloheterocycle substituted quinuclidine derivatives
08/29/2007EP1824847A2 Pyridazinone compounds
08/29/2007EP1824846A2 Novel compounds for the treatment of neurological disorders
08/29/2007EP1824845A1 1-arylpyrazoles and their use as pesticides
08/29/2007EP1824844A1 Pyrazine dicarboxamides and the use thereof
08/29/2007EP1824843A2 Inhibitors of protein kinases
08/29/2007EP1824842A2 Inhibitors of 11- hydroxyl steroid dehydrogenase type 1 and methods of using the same
08/29/2007EP1824841A1 Substituted pyrrole derivative
08/29/2007EP1824840A1 Compounds having activity at nk3 receptor and uses thereof in medicine
08/29/2007EP1824839A2 Substituted biaryl analogues
08/29/2007EP1824838A1 Novel compounds
08/29/2007EP1824837A1 Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
08/29/2007EP1824835A1 Heteroaromatic glucokinase activators
08/29/2007EP1824834A1 Meta-substituted thiazolidinones, the production thereof and their use as medicaments
08/29/2007EP1824833A2 Preparation of telmisartan salts with improved solubility
08/29/2007EP1824832A1 Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
08/29/2007EP1824830A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality
08/29/2007EP1824829A1 3-substituted pyridine derivatives as h3 antagonists
08/29/2007EP1824826A1 Aryl sulfonic pyridoxines as antiplatelet agents
08/29/2007EP1824825A1 Substituted pyridoxines as anti-platelet agents
08/29/2007EP1824822A2 Novel 4-aminopiperidine derivatives as plasmepsin ii inhibitors
08/29/2007EP1824820A2 Substituted tetracyclic tetrahydrofuran,pyrrolidine and tetrahydrothiophene derivatives
08/29/2007EP1824819A1 Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
08/29/2007EP1824818A2 2ALFA-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1ALFA-HYDROXYVITAMIN D3 AND THEIR USES
08/29/2007EP1824817A1 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
08/29/2007EP1824812A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment
08/29/2007EP1824809A2 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
08/29/2007EP1824564A2 Method for treating glioma
08/29/2007EP1824563A1 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
08/29/2007EP1824509A2 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
08/29/2007EP1824504A1 Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives
08/29/2007EP1824502A1 Compositions comprising sclareol or derivatives thereof and uses thereof
08/29/2007EP1824498A2 Methods and compositions for treating cellular proliferative diseases
08/29/2007EP1824497A1 Macrolone compounds
1 ... 3606 3607 3608 3609 3610 3611 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 ... 7860